SCHEMBL26647809

SCHEMBL26647809

COc1ccc(CN(CCOP(=O)(O)O)C(=O)CCCCc2cccc(CCCCCC3CCCCC3)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 1/20 0.42
▸ SLC2A1 P11166 1/20 0.41
▸ BCHE P06276 2/20 0.41
▸ ACHE P22303 2/20 0.41
▸ PPARA Q07869 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ OPRM1 P35372 1/20 0.40
▸ SLC6A4 P31645 2/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ S1PR4 O95977 1/20 0.39
▸ S1PR1 P21453 1/20 0.39
▸ S1PR3 Q99500 1/20 0.39
▸ S1PR5 Q9H228 1/20 0.39
▸ ALOX5 P09917 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25456797 1.00 SRC (0.42) SRCSLC2A1BCHEACHEPPARA
SCHEMBL25456793 1.00 SRC (0.42) SRCSLC2A1BCHEACHEPPARA
Ammonia Solution, Strong SCHEMBL25170046 0.99 SRC (0.42) SRCSLC2A1BCHEACHEPPARA
Ammonia Solution, Strong SCHEMBL25176194 0.99 SRC (0.42) SRCSLC2A1BCHEACHEPPARA
Ammonia Solution, Strong SCHEMBL25169999 0.99 SRC (0.42) SRCSLC2A1BCHEACHEPPARA
SCHEMBL25456763 0.94 SRC (0.45) SRCBCHEACHEPPARAALDH1A1
Ammonia Solution, Strong SCHEMBL25175603 0.93 SRC (0.44) SRCBCHEACHEPPARAALDH1A1
SCHEMBL25456788 0.84 ALOX5 (0.48) BCHEACHES1PR4S1PR1S1PR3
SCHEMBL25456761 0.80 SLC2A1 (0.51) SLC2A1S1PR1S1PR3ALOX5NPC1
SCHEMBL25456753 0.80 ALOX5 (0.52) S1PR4S1PR1S1PR3S1PR5ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 — — US disclosed
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802135-B2 Lysophosphatidic acid derivative LPAR4, LPAR2, LPAR1 SRC 2278/4885SLC2A1 3997/4885BCHE 4294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback